Such mutations often affect structural domains of the SMAD4 protein, such as the DNA-binding region, thereby preventing its effective binding with the TGF-β receptor, interrupting the normal TGF-β signaling pathway, and disrupting the tumor suppression mechanism, which promotes the formation and progression of tumors.2 This evidence concerns the gene SMAD4 and neoplasm.